Also listed on Aclaris Therapeutics, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Jun 11, 2035 · Low confidence
20-year base term ends Jun 11, 2035
Jun 11, 2015
Jun 11, 2035
Aug 25, 2020
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: Low. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 11, 2015, when application 14/737,360, the earliest non-provisional in its chain, was filed (this one was filed Apr 10, 2019); a parent in its chain could not be resolved (the next row) | Jun 11, 2035 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,335,391, US 9,974,773) | resolves to Jun 11, 2035, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 15984918, 14737360, 14737360 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Jun 11, 2035 | Low confidence |
This family
| US 9,801,857 | In force Jun 2035 | Jun 2035 |
| US 9,974,773 | In force Jun 2035 | Jun 2035 |
| US 10,335,391 | In force Jun 2035 | Jun 2035 |
| US 10,751,325 | this patent Jun 2035 | Jun 2035 |
| US 11,517,560 | In force Jun 2035 | Jun 2035 |
| US 12,350,255 | In force Jun 2035 | Jun 2035 |
| Application 19/210,851 | Pending not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 13, 2019 Reel 50038, frame 231 | Sarpotdar, Pramod; Warner, Kevin; Ahluwalia, Gurpreet; Kuang, Amy; Zhang, Steven | Allergan, Inc. | Assignment of Assignor's Interest |
| Aug 13, 2019 Reel 50038, frame 283 | Allergan, Inc. | Aclaris Therapeutics, Inc. | Assignment of Assignor's Interest |
| Nov 1, 2019 Reel 50905, frame 290 | Aclaris Therapeutics, Inc. | Epi Health, LLC | Assignment of Assignor's Interest |
| Mar 14, 2022 Reel 59364, frame 509 | Epi Health, LLC | Evening Post Group, LLC | Security Interest |
| Jan 11, 2023 Reel 62347, frame 129 | Evening Post Group, LLC | Epi Health, LLC | Release of Security Interest |
| Dec 11, 2024 Reel 69557, frame 372 | Epi Health, LLC | Mayne Pharma LLC | Assignment of Assignor's Interest |
| Oct 26, 2026 Reel 76754, frame 805 | Epi Health, LLC | Mayne Pharma LLC | Corrective Assignment to Correct the Properties Section by Including Application Numbers That Were Omitted from the Previously Recorded Assignment as Well as Include Pages Missing from Assignment Previously Recorded on Reel 69557 Frame 372. Assignor(S) Hereby Confirms the Assignment of Assignor's Interest. |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 10,335,391, US 9,974,773, ends no earlier than this term, so it caps nothing.